ストックスクリーナーアプリを入手
0.885
0.57%
0.005
前日終値:
$0.88
開ける：
$0.89
24時間の取引高:
5,912
Relative Volume:
0.16
時価総額：
$3.47M
収益：
-
当期純損益:
$-736.70K
株価収益率:
-88.50
EPS:
-0.01
ネットキャッシュフロー:
$-4.14M
1週間 パフォーマンス:
-3.28%
1か月 パフォーマンス:
-14.90%
6か月 パフォーマンス:
-25.63%
1年 パフォーマンス:
-57.86%
1日の値動き範囲:
$0.87
$0.8909
1週間の範囲:
$0.85
$0.9424
52週間の値動き範囲:
$0.802
$2.9799
Xortx Therapeutics Inc Stock (XRTX) Company Profile
XRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.885 | 3.47M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc (XRTX) 最新ニュース
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - mx.advfn.com
XORTX Therapeutics Inc. issues common units via private placement - McCarthy Tétrault
XORTX Therapeutics looks to raise $3M through private placement - MSN
XRTX Initiates $3 Million Private Placement to Fund Key Projects - GuruFocus
XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program - Nasdaq
MT Newswires Canada Stocks To Watch: Endeavour Mining; Quantum BioPharma; XORTX Therapeutics - marketscreener.com
XORTX Announces USD $3 Million Offering - GlobeNewswire
XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs - TipRanks
Late-Stage Biotech XORTX Secures $3M Funding to Advance Novel Gout Treatment Program - Stock Titan
XORTX Therapeutics Inc. announced that it expects to receive $2.999999 million in funding - marketscreener.com
XORTX Therapeutics reports Q1 financials to SEC By Investing.com - Investing.com South Africa
XORTX Therapeutics Reports Q1 2025 Financial Results - TipRanks
XORTX Therapeutics reports Q1 financials to SEC - Investing.com
XORTX Therapeutics Delays Yearly Report Filing - TipRanks
XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks
XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com
XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire
XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com
FDA Green Lights XORTX Path to NDA: Key Steps Revealed for Novel Gout Treatment XORLO - Stock Titan
XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com
XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks
XORTX Announces Grant of European Patent - GlobeNewswire
XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan
XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN
XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan
1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
Xortx Therapeutics Inc (XRTX) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):